Hepatitis Monthly
Volume:4 Issue: 3, Spring 2004

The addition of ribavirin (RIBA) to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monotherapy to 40-45% in combination therapy. The aim of this study is to assess the therapeutic efficacy and safety of IFN alpha (PDferon B®) in combination with RIBA on Iranian patients with chronic hepatitis C (CHC). 48 naive patients aged 18 years or more with CHC were enrolled and treated with 3 mega units (MU) IFN alpha-2b three times a week plus 800-1000 mg RIBA per day for 48 weeks. Follow-up after therapy was 6 months. The efficacy was evident at the end of treatment and at the end of follow-up in terms of sustained normalization of alanine aminotransferase and sustained serum HCV-RNA loss. The rate of sustained biochemical and virologic response were 68.3% and 78%, respectively. Virologic response was 80.9% and 86.4% at weeks 12 and 48 as well. Any patient didn''t have serious complication. Although we had no control group who used standard IFN, our preliminary finding showed acceptable and promising response rate of PDferon. On the other hand, it seems that adverse events with PDferon are as like as other standard IFNs. Fax: +98-21-8975730

In this report we aim to assess therapeutic efficiency and safety of particular brand of IFN-alpha 2b (PDferon B®) in patients with HBeAg negative-CHB in Iran. Patients and 28 patients (23 male, 5 female, mean age 28+- 12.4 years) with HBeAg-negative Chronic Hepatitis B enrolled. All of them received Interferon-alpha 2b (PDferon B®) 5-6 MU per dose and totally 15-35 MU per week for six months. Demographic characteristics, sex, age time of diagnosis, histological scoring and family history of HBV infection considered in analysis. All except one received the drug until finishing the course of treatment. 10.7 %determined as not responsive neither biochemically nor virologically. 85.7 were responder by considering one of the criteria. 60.7 % patients had complete response (HBV DNA negative and normal ALT) and 4.6% HBsAg seroconvert. Considering high response rate of the current study, the efficacy of PDferon B®) is similar to other Interferons in different studies.

In this report we aim to assess therapeutic efficiency and safety of particular brand of IFN-alpha 2b (PDferon B®) in patients with HBeAg negative-CHB in Iran. Patients and 28 patients (23 male, 5 female, mean age 28+- 12.4 years) with HBeAg-negative Chronic Hepatitis B enrolled. All of them received Interferon-alpha 2b (PDferon B®) 5-6 MU per dose and totally 15-35 MU per week for six months. Demographic characteristics, sex, age time of diagnosis, histological scoring and family history of HBV infection considered in analysis. All except one received the drug until finishing the course of treatment. 10.7 %determined as not responsive neither biochemically nor virologically. 85.7 were responder by considering one of the criteria. 60.7 % patients had complete response (HBV DNA negative and normal ALT) and 4.6% HBsAg seroconvert. Considering high response rate of the current study, the efficacy of PDferon B®) is similar to other Interferons in different studies.